Globe Newswire

PRINCE GEORGE, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) -- United Steelworkers union (USW) Local 1-2017 is pleased to welcome over 30 workers from Winton Homes Ltd., part of the Sinclar Group Forest Products family in Prince George. These workers have been certified by the B.C. Labour Relations Board to become part of the USW.

“We are thrilled to welcome our new members from Winton Homes Ltd. into the United Steelworkers family,” said Brian O'Rourke,... (continue reading...)

CHICAGO, May 09, 2024 (GLOBE NEWSWIRE) -- GoHealth, Inc. (NASDAQ: GOCO) (“GoHealth” or the “Company”), a leading health insurance marketplace and Medicare-focused digital health company, today announced financial results for the three months ended March 31, 2024.

First Quarter Highlights

• First quarter 2024 net revenues of $185.6 million, a slight increase compared to $183.2 million in the prior year period.
• First quarter 2024 Submissions of 216,148, a... (continue reading...)

SHANGHAI, China, May 09, 2024 (GLOBE NEWSWIRE) -- Atour Lifestyle Holdings Limited (“Atour” or the “Company”) (NASDAQ: ATAT), a leading hospitality and lifestyle company in China, today announced that it will report its unaudited financial results for the first quarter 2024 on Thursday, May 23, 2024, before the U.S. markets open.

The Company will host a conference call at 7:00 AM U.S. Eastern time on Thursday, May 23, 2024 (or 7:00 PM Beijing/Hong Kong time... (continue reading...)

Q1 2024 Financial Highlights

• Q1 exiting SaaS ARR up 12% Y/Y to $28.5 million;
• Total ARR up 7% Y/Y to $42.5 million;
• SaaS NRR of 106%;
• Bookings up 18% Y/Y to $9.1 million, 34% of which were partner-attached;
• Adjusted EBITDA margin of 25.9% or $4.2 million;
• Gross profit margin of 57%;
• RPO of $26.8 million;
• Repurchased 51,800 shares at a total cost of $0.5 million, with an average price of $8.76 per share.

CALGARY, Alberta, May 09, 2024 (GLOBE NEWSWIRE) --  Sylogist Ltd.... (continue reading...)

• Presented data which, along with ongoing IND-enabling studies, demonstrate efficacy and pharmacology of ABO-101 in non-human primates (NHPs), supporting continued development as a potential novel gene editing therapy for patients with primary hyperoxaluria type 1 (PH1)
• Other presentations include preclinical evidence of editing in the central nervous system (CNS) using novel CRISPR-Cas systems, signaling potential for an effective STMN2-targeting gene editing approach... (continue reading...)